Celanese Corporation (CE) shows varied performance with its shares underperforming on certain days compared to competitors, while it flourishes on others. Notably, the company has achieved value positions, outperformed competitors on strong trading days, and seen a 39% increase over a six-month period and significant year-to-date growth. Financial analysis figures like Price-to-Free-Cash-Flow and Debt-to-Equity ratio together with relevant earnings estimates provide a structure for assessment. However, awry signals come from the company missing both revenues and earnings estimates in Q4, and receiving a consistent consensus recommendation of “Hold” from analysts. The potential risks are tempered by positive factors such as the announcement of increasing price for Acetate Tow, manufacturing commencement at VAE Unit in Singapore, and the extension of long-term feedstock contract in China. Merging efforts that resulted in productivity boosts are captured when they partnered with Glaukos for Glaucoma treatment and formed a JV with Mitsui for Food Ingredients. The expectation for future performance is highlighted by Q1 2024 Earnings Call Transcripts and the 2024 First Quarter Earnings Conference scheduled for May 9.
Celanese Corporation CE News Analytics from Fri, 15 Dec 2023 08:00:00 GMT to Thu, 30 May 2024 13:40:11 GMT -
Rating +3
- Innovation +4
- Information +6
- Rumor -2
